Home » Stocks » EIGR

Eiger BioPharmaceuticals, Inc. (EIGR)

Stock Price: $9.25 USD 0.50 (5.71%)
Updated December 4, 4:00 PM EST - Market closed

EIGR Stock Price Chart

Key Info

Market Cap 300.92M
Revenue (ttm) n/a
Net Income (ttm) -63.17M
Shares Out 29.88M
EPS (ttm) -2.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $9.25
Previous Close $8.75
Change ($) 0.50
Change (%) 5.71%
Day's Open 8.76
Day's Range 8.68 - 9.38
Day's Volume 537,458
52-Week Range 4.91 - 15.66

EIGR Stock News

Seeking Alpha - 4 days ago

Eiger is solely focused on rare disease opportunities with its big target being hepatitis delta virus. Eiger's first therapy Zokinvy just got approved which nets the company an important Prior...

PRNewsWire - 1 week ago

PALO ALTO, Calif., Nov. 25, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra...

Zacks Investment Research - 1 week ago

Eiger (EIGR) gets FDA approval for Zokinvy for the treatment of Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies.

Benzinga - 1 week ago

The FDA approved Eiger Biopharmaceuticals Inc (NASDAQ: EIGR)'s lonfarnib Friday for the treatment of Hutchinson-Gilford Progeria Syndrome, commonly referred to as progeria, as well as processi...

PRNewsWire - 2 weeks ago

PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of first-in-class therapies for serious rare an...

PRNewsWire - 1 month ago

PALO ALTO, Calif., Nov. 2, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted, first-in-class therapies for serious...

Zacks Investment Research - 1 month ago

Eiger (EIGR) gains on positive results from the ILIAD study on peginterferon lambda-1a (lambda) in outpatients with mild-to-moderate COVID-19.

Seeking Alpha - 1 month ago

Eiger BioPharmaceuticals: Peginterferon Lambda COVID-19 Data Very Positive

The Motley Fool - 1 month ago

Investors were excited about the company's positive results from a COVID-19 clinical study

Zacks Investment Research - 2 months ago

Eiger (EIGR) declines on disappointing study results on candidate, peginterferon lambda-1a (lambda), in outpatients with mild and uncomplicated COVID-19.

The Motley Fool - 2 months ago

The company reported disappointing news from a clinical study targeting COVID-19 outpatients.

24/7 Wall Street - 2 months ago

Eiger BioPharmaceuticals Inc. (NASDAQ: EIGR) has announced disappointing results from an investigator-sponsored study of Peginterferon Lambda-1a (Lambda) in outpatients with mild and uncomplic...

Seeking Alpha - 2 months ago

Short-term catalyst is the near-certain approval of lonafarnib in HGPS.

Zacks Investment Research - 2 months ago

Investors need to pay close attention to Eiger BioPharmaceuticals (EIGR) stock based on the movements in the options market lately.

PRNewsWire - 3 months ago

PALO ALTO, Calif., Aug. 31, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.

Zacks Investment Research - 3 months ago

Eiger BioPharmaceuticals (EIGR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Seeking Alpha - 4 months ago

Coronavirus Pandemic: Regeneron And Eiger BioPharmaceuticals Positioned To Benefit From Opportunity In Treating Early Stage And At-Risk Patients

Other stocks mentioned: REGN
Seeking Alpha - 4 months ago

A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.

Other stocks mentioned: BCRX, BNTX, BSGM, CYDY, GILD, IMUX, PFE, REGN
Zacks Investment Research - 4 months ago

Eiger BioPharma (EIGR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 5 months ago

Eiger BioPharmaceuticals (EIGR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

PRNewsWire - 6 months ago

PALO ALTO, Calif., May 29, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced today that, due to public health and safety concerns related to the COVID-19 global pand...

PRNewsWire - 6 months ago

PALO ALTO, Calif., May 26, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-...

PRNewsWire - 6 months ago

PALO ALTO, Calif., May 19, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-...

Zacks Investment Research - 6 months ago

Eiger BioPharmaceuticals (EIGR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Seeking Alpha - 6 months ago

Eiger BioPharmaceuticals: Promising COVID-19 Effort With Peginterferon Lambda Just Entering Clinical Trials

Zacks Investment Research - 7 months ago

As of late, it has definitely been a great time to be an investor Eiger BioPharmaceuticals

Zacks Investment Research - 8 months ago

Eiger (EIGR) completes rolling submission of the NDA seeking approval for lonafarnib as a treatment for progeria and progeroid laminopathies, ultra-rare diseases causing accelerated aging in c...

Zacks Investment Research - 1 year ago

Eiger BioPharma (EIGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 1 year ago

EIGR has an NDA upcoming for an ultrarare disease, but another phase 3 trial ongoing for the first antiviral against the hepatitis D virus.

24/7 Wall Street - 1 year ago

Tuesday was a breakout day for a few biotech companies, and that was the case even before news broke that the U.S. and China would be meeting at the G20 meeting in Japan.

Other stocks mentioned: BHVN, CALA, RMTI

About EIGR

Eiger BioPharmaceuticals, a late-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase 3 clinical trial to treat hepatitis delta virus (HDV) infection. The company's product candidate also include Lambda, which targets type III interferon receptors that is in Phase 2 clinical trial; Lonafarnib for the treatment of progeria ... [Read more...]

Industry
Biotechnology
CEO
Krisztina Zsebo
Employees
29
Stock Exchange
NASDAQ
Ticker Symbol
EIGR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for EIGR stock is "Strong Buy." The 12-month stock price forecast is 31.67, which is an increase of 242.38% from the latest price.

Price Target
$31.67
(242.38% upside)
Analyst Consensus: Strong Buy